Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 230 | 35 | 193 |
| Samples | 223 | 31 | 190 |
| Peptides | 145 | 20 | 130 |
Function
KRTAP13-1 · Keratin associated protein 13-1
Hair keratins and hair keratin-associated proteins (KAPs), such as KRTAP13-1, are the main structural proteins of hair fibers (Rogers et al., 2002 [PubMed 12359730]).[supplied by OMIM, Mar 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000355459 | Q8IUC0 | 230 | 145 |
Gene Properties
Recurrent Mutations
All 145 amino-acid changes on canonical ENST00000355459 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRTAP13-1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRTAP13-1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Pancreatic Carcinoma | 0/89 0% | 29/1611 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 11/810 1% |
| Melanoma | 2/210 1% | 27/1899 1% |
| Endometrial Carcinoma | 1/42 2% | 8/612 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 15/1390 1% |
| Colorectal Carcinoma | 7/143 5% | 32/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Prostate Carcinoma | 3/13 23% | 3/2105 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Other Sarcomas | 1/69 1% | 1/699 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 5/2534 0% |
| Kidney Carcinoma | 1/85 1% | 2/1862 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 1/2640 0% |
| Breast Carcinoma | 0/144 0% | 1/3264 0% |
Mutation Distribution
Where KRTAP13-1 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRTAP13-1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 1 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 230 mutations in KRTAP13-1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|